Two types of EGFR‐targeting drugs have been developed, monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs),11 and development of EGFR TKIs in particular was an important milestone in the targeted therapy of NSCLC.3, 12. Here, EGFR is linked to non-small cell lung carcinoma.